spacer
home > ebr > spring 2002 > has biotechnology forgotten the eye?
PUBLICATIONS
European Biopharmaceutical Review

Has Biotechnology Forgotten the Eye?

For over two decades, the biotechnology industry has been developing therapeutic products based on large molecules. The majority of these products are proteins, from the first trailblazers such as insulin and growth hormone, to the blockbusters like EPO, and subsequently wider classes of molecules such as cytokines, enzymes and antibodies. Yet in all this time, there have been few chronic clinical studies of proteins in eye disease. This is not because the markets are unattractive. Millions of patients suffer from poorly treated diseases in ophthalmology - such as age-related macular degeneration (AMD), or diabetic retinopathy - yet there are still very few medical treatments available. The exception that clearly demonstrates the attractive nature of the ophthalmology market is Visudyne’, developed by QLT Therapeutics Inc. and Novartis. The product transformed QLT from a small Canadian cancer company into a significantly capitalised, internationally known biotech company. This change occurred when the QLT concept of photodynamic therapy, which had previously been applied for several years to cancer with limited success, was applied to AMD. So given this success, why is biotech activity so limited in the eye?


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Dr Tom S Shepherd, President and Chief Executive Officer of Neurotech S.A.

Dr Tom Shepherd is President and Chief Executive Officer of Neurotech S.A., a French-based biotechnology company based in the Genopole science park in Evry near Paris, with a US R&D subsidiary based in Lincoln, Rhode Island. Prior to joining the company in 1998, he was Vice President of Business Development at Intrabiotics Inc, a Californian biotech company now quoted on Nasdaq.
Tom gained his PhD in Biochemistry from the University of Strathclyde in Glasgow, UK, and has 20 years of international management experience in pharmaceuticals and biotechnology, having worked in the UK, the US, Australia, South Korea and France, with a range of companies including Sandoz (now Novartis), Cortecs plc, and ICN Pharmaceuticals.

spacer
Dr Tom S Shepherd
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Vaisala Introduces CAB100 Industrial Cabinet for Cleanrooms

Vaisala, a global leader in weather, environmental, and industrial measurements, launches its newest offering for centralized environmental monitoring in cleanrooms: The CAB100 integrates Vaisala’s world-class instruments for monitoring parameters into a simple, pre-configured enclosure.
More info >>

White Papers

Time lapse photography to demonstrate the potential antimicrobial abilities of Dycem contamination control flooring

Dycem

A defined volume of bioluminescent reporter bacteria was deposited onto 20 mm x 20 mm coupons of Dycem flooring, vinyl tile and ITW Alma tacky mat. Through monitoring of bacterial bioluminescence, metabolic inhibition was observed on all three surfaces however the effect occurred more rapidly on Dycem flooring than on vinyl or ITW Alma. Recovery counts after three hours of exposure to the floor surfaces showed between a 65% and 100% decrease in the number of viable organisms recovered from Dycem flooring compared to controls. On vinyl and ITW Alma flooring, there were slight increases in the number of viable survivors recovered compared to controls. Dycem flooring inhibited the metabolic activity and reduced the number of viable survivors recovered of Salmonella enterica Serovar Typhimurium DT104 pGLITE. It remains unclear as to whether this effect is attributable to the impregnated biocide or rapid drying of the inoculum on this surface.
More info >>

 
Industry Events

PDA Europe Annual Meeting 2019

24 June 2019, Hilton Amsterdam

Featuring updates from international regulatory agencies as well as industry, this promises to become another highlight in the 2019 event calendar and is a meeting not to be missed!
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement